Back HIV/AIDS HIV/AIDS Topics HIV Treatment

HIV Medicine Association Cautions Against Excessive HIV-Related Testing

The HIV Medicine Association (HIVMA) has released new recommendations calling on HIV care providers to avoid routine use of unnecessary monitoring tests, including frequent CD4 T-cell counts and viral load tests for people on stable suppressive antiretroviral therapy.

alt

Read more:

Tenofovir Resistance May Develop in More than Half of Patients Failing Treatment

More than half of people who experienced failure of a tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to tenofovir, a meta-analysis of drug resistance studies published in the January 28 online edition of Lancet Infectious Diseases has shown. The study found that the prevalence of tenofovir resistance after first-line treatment failure ranged from 20% in Western Europe and North America to 56%-60% in sub-Saharan Africa.

alt

Read more:

Updated Antiretroviral Therapy Guidelines Emphasize Benefits of Early HIV Treatment

The U.S. Department of Health and Human Services has updated itsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents to reflect findings from the START and TEMPRANO trials demonstrating the clinical benefits of early initiation of antiretroviral therapy (ART) with a pre-treatment CD4 T-cell count above 500 cells/mm3.

alt

Read more:

Long-term Tenofovir Use Associated with Increased Risk of Serious Liver Disease

Long-term therapy with the antiretroviral drug tenofovir (Viread, also in several coformulations including Truvada and Atripla) increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published in the January 18 online edition of AIDS. Researchers found that 5-year cumulative use of the drug increased the relative risk of serious liver disease by 46%.

alt

Read more:

ViiV and Janssen To Collaborate on Long-Acting Injectable HIV Treatment

ViiV Healthcare and Janssen have announced a plan to work together on the development of long-acting injectable HIV treatment using ViiV's investigational integrase inhibitor cabotegravir and an injected formulation of Janssen's currently available oral NNRTI rilpivirine (Edurant).

alt

Read more:

Study Sheds Light on Ongoing HIV Replication in Lymph Node Reservoirs

HIV may continue to replicate in sanctuary sites in lymphoid tissues despite antiretroviral therapy, and may not necessarily develop drug resistance mutations, researchers reported in the January 27 online edition of Nature. While the existence of HIV reservoirs is well known, further characterizing the behavior of the virus in these sites could suggest new approaches to a cure.

alt

Read more:

HIV Patients with Rapid Disease Progression May Have Worse Immune Recovery

People with HIV who experience fast disease progression with a rapid drop in their CD4 T-cell count may be less likely to regain a normal CD4 level after starting antiretroviral therapy (ART), according to research from the CASCADE Collaboration published in the November 2015 edition of AIDS.

alt

Read more: